The British Medical Association has placed 200 of its 600 England-based staff at risk of redundancy, according to an exclusive Guardian report published on July 4, 2026 — a restructuring that exposes a deep and long-running financial rupture within the UK's largest doctors' trade union and professional body.

The BMA is losing millions of pounds annually despite membership reaching a record 200,000. That paradox has a structural explanation: since 2008, the association has required £86.8 million in cross-subsidies from the British Medical Journal — which it owns — simply to remain solvent. That averages £5.1 million per year over nearly two decades, making the BMJ less a journalistic enterprise than a financial stabiliser for an organisation that cannot cover its own operating costs from subscriptions and services alone.

The redundancy programme is already advanced. Industrial relations officer (IRO) posts are being cut from 23.5 full-time equivalents to 14, and three of seven heads of region are slated for elimination. Up to 20 of the 45 staff working across the board of science and board of ethics face redundancy — a cut that would hollow out the BMA's evidence and policy infrastructure at the precise moment NHS workforce and clinical governance questions are most contested. A redundancy scheme was already referenced by the BMA itself in an Instagram post from June 9, 2026, suggesting the April 2026 round predates the current escalation.

The GMB union, which represents most BMA employees, has lodged a formal complaint that the association breached its own HR procedures and sought to prevent staff from speaking publicly. The union's members passed a vote of no confidence in chief executive Rachel Podolak on a 72% turnout, with 91% supporting the motion — a result that strips Podolak of any claim to the confidence of her workforce even as she leads the restructuring. Chairs of 110 local negotiating committees have written directly to Podolak and deputy chair of council Dr Emma Runswick to condemn the planned loss of IRO and head of region posts. The BMA's consultants committee has passed its own critical motion on the IRO cuts.

There is also a credibility gap. When questioned by the Guardian, the BMA described the likely job losses as "as few as 20" — a figure at odds with the 200 at-risk notifications issued in formal consultation with GMB representatives. The BMA's public-facing news and opinion pages, as of early July 2026, carry no disclosure to members about the restructuring, its financial drivers, or the human cost. The most prominent communications on those pages concern the June 29 announcement that resident doctors in England had accepted a pay and jobs offer and that industrial action would end, with pay review kept "on notice" pending full pay restoration.

That timing is awkward, though not coincidental. The resident doctors' ballot closed days before the staffing crisis broke publicly, following 15 rounds of strikes and a deal that will push the best-paid resident doctor basic salaries to £77,348. The BMA has spent enormous organisational energy and resource managing that dispute. The internal restructuring, running in parallel and apparently predating the ballot's conclusion, suggests the financial pressure has been building regardless of the industrial calendar.

The picture that emerges is of an institution operating a structural deficit disguised by an asset — the BMJ — that cannot indefinitely absorb the losses. The IRO and regional head cuts are not peripheral. IROs are the operational backbone of workplace representation for doctors in NHS trusts; reducing that capacity by roughly 40% will materially weaken the BMA's ability to represent members in local disputes, grievances, and contract negotiations. That is the core function of a trade union. Cutting it while simultaneously telling members nothing about the reorganisation is the tension that has driven the no-confidence vote and the LNC chairs' letter.

The BMA has not yet publicly confirmed the full scope of the restructuring, the timeline for final redundancy decisions, or what structural changes it intends to make to its revenue model. Whether the BMJ subsidy continues, is wound down, or is supplemented by subscription reform or service cuts remains publicly unaddressed. For an organisation that spent much of 2024 and 2025 demanding transparency from NHS employers over pay and workforce planning, the opacity of its own house is the sharpest internal contradiction it now faces.